Prognostic significance of glycolytic metabolic change related to HIF-1α in oral squamous cell carcinomas

Korean Journal of Pathology

Volumn 44, Issue 4, 2010, Pages 360-369

  Hong, Sook Hee ^a   Roh, Sang Young ^a   Ko, Yoon Ho ^a   Won, Hye Sung ^a   Lee, Myung Ah ^a   Woo, In Sook ^a   Byun, Jae Ho ^a   Kang, Jin Hyoung ^a   Hong, Young Seon ^a   Jung, Chan Kwon ^a   Kim, Yeon Sil ^a   Ju, Young Hoon ^a   Kim, Min Sik ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

Carcinoma; HIF1A protein; human; Lactate dehydrogenase 5; Pyruvate dehydrogenase (acetyl transferring) kinase; squamous cell

Indexed keywords

EID: 77957340556     PISSN: 17381843     EISSN: None     Source Type: Journal    
DOI: 10.4132/KoreanJPathol.2010.44.4.360     Document Type: Article

References (29)

1. Chen AY, Schrag N, Hao Y, Stewart A, Ward E. Changes in treatment of advanced oropharyngeal cancer, 1985-2001. Laryngoscope 2007; 117: 16-21.
2. Stell PM, McCormick MS. Cancer of the head and neck: are we doing any better? Lancet 1985; 2: 1127.
3. Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol 2001; 18: 243-59.
4. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy: an international multi-center study. Radiother Oncol 2005; 77: 18-24.
5. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-32.
6. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-14.
7. Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 1994; 269: 23757-63.
8. Semenza GL. HIF-1 mediates the Warburg effect in clear cell renal carcinoma. J Bioenerg Biomembr 2007; 39: 231-4.
9. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL. Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway-a report of the Tumour Angiogenesis Research Group. J Clin Oncol 2006; 24: 4301-8.
10. Lukacova S, Sorensen BS, Alsner J, Overgaard J, Horsman MR. The impact of hypoxia on the activity of lactate dehydrogenase in two different pre-clinical tumour models. Acta Oncol 2008; 47: 941-7.
11. Wigfield SM, Winter SC, Giatromanolaki A, Taylor J, Koukourakis ML, Harris AL. PDK-1 regulates lactate production in hypoxia and is associated with poor prognosis in head and neck squamous cancer. Br J Cancer 2008; 98: 1975-84.
12. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006; 3: 177-85.
13. Aebersold DM, Burri P, Beer KT, et al. Expression of hypoxiainducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001; 61: 2911-6.
14. Koukourakis MI, Giatromanolaki A, Danielidis V, Sivridis E. Hypoxia inducible factor (HIf1alpha and HIF2alpha) and carbonic anhydrase 9 (CA9) expression and response of head-neck cancer to hypofractionated and accelerated radiotherapy. Int J Radiat Biol 2008; 84: 47-52.
15. Lartigau E, Le Ridant AM, Lambin P, et al. Oxygenation of head and neck tumors. Cancer 1993; 71: 2319-25.
16. Lartigau E, Lusinchi A, Weeger P, et al. Variations in tumour oxygen tension (pO2) during accelerated radiotherapy of head and neck carcinoma. Eur J Cancer 1998; 34: 856-61.
17. Pentenero M, Gandolfo S, Carrozzo M. Importance of tumor thickness and depth of invasion in nodal involvement and prognosis of oral squamous cell carcinoma: a review of the literature. Head Neck 2005; 27: 1080-91.
18. Cohen NA, Lai SY, Ziober AF, Ziober BL. Dysregulation of hypoxia inducible factor-1alpha in head and neck squamous cell carcinoma cell lines correlates with invasive potential. Laryngoscope 2004; 114: 418-23.
19. Sahlgren C, Gustafsson MV, Jin S, Poellinger L, Lendahl U. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci U S A 2008; 105: 6392-7.
20. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4: 891-9.
21. Lu H, Dalgard CL, Mohyeldin A, McFate T, Tait AS, Verma A. Reversible inactivation of HIF-1( prolyl hydroxylases allows cell metabolism to control basal HIF-1(. J Biol Chem 2005; 280: 41928-39.
22. Katsuta M, Miyashita M, Makino H, et al. Correlation of hypoxia inducible factor-1alpha with lymphatic metastasis via vascular endothelial growth factor-C in human esophageal cancer. Exp Mol Pathol 2005; 78: 123-30.
23. Liang X, Yang D, Hu J, Hao X, Gao J, Mao Z. Hypoxia inducible factor-alpha expression correlates with vascular endothelial growth factor-C expression and lymphangiogenesis/angiogenesis in oral squamous cell carcinoma. Anticancer Res 2008; 28: 1659-66.
24. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer 2003; 89: 877-85.
25. Gatenby RA, Gawlinski ET, Gmitro AF, Kaylor B, Gillies RJ. Acidmediated tumor invasion: a multidisciplinary study. Cancer Res 2006; 66: 5216-23.
26. Elstrom RL, Bauer DE, Buzzai M, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004; 64: 3892-9.
27. Amornphimoltham P, Sriuranpong V, Patel V, et al. Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin Cancer Res 2004; 10: 4029-37.
28. Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000; 60: 1541-5.
29. Winter SC, Shah KA, Han C, et al. The relation between hypoxiainducible factor (HIF)-1alpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer. Cancer 2006; 107: 757-66.